Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al-Reference-Cited by-同舟云学术

Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al

Published:2020-08-28 Issue: Volume: Page:annrheumdis-2020-218778
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Notz Quirin^ORCID,Meybohm Patrick,Kranke Peter,Weismann Dirk,Lotz Christopher,Schmalzing Marc

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference6 articles.

1. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

2. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19;Boulware;N Engl J Med,2020

3. Observational study of hydroxychloroquine in hospitalized patients with Covid-19;Geleris;N Engl J Med,2020

4. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial;Skipper;Ann Intern Med,2020

5. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab;Avouac;Ann Rheum Dis,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy;European Journal of Clinical Microbiology & Infectious Diseases;2024-02-15

2. Systemic Lupus Erythematosus and COVID-19;Current Rheumatology Reports;2023-07-21

3. Anakinra/rituximab;Reactions Weekly;2023-04-22

4. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus;Arthritis & Rheumatology;2022-11-11

5. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease;Translational Research;2021-06